{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:59:16Z","timestamp":1790812756115,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00262-020-02493-z","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T03:05:36Z","timestamp":1580785536000},"page":"641-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model"],"prefix":"10.1007","volume":"69","author":[{"given":"Brian W.","family":"Simons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayana T.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-8002","authenticated-orcid":false,"given":"Raphael P.","family":"Viscidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"issue":"1","key":"2493_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11648\/j.ajcem.20170501.11","volume":"5","author":"CK Miranti","year":"2017","unstructured":"Miranti CK, Koul HR (2017) Meeting Report of Joint Society of Basic Urologic Research (SBUR) and European Society of Urological Research (ESUR) symposium fall 2017. Am J Clin Exp Urol 5(1):1\u201392 (Abstract# P54)","journal-title":"Am J Clin Exp Urol"},{"key":"2493_CR2","unstructured":"National Cancer Institute (2019) Cancer Stat Facts: Prostate Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed Dec 2019"},{"key":"2493_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/cancers4010193","volume":"4","author":"A Kiessling","year":"2012","unstructured":"Kiessling A, Wehner R, Fussel S, Bachmann M, Wirth MP, Schmitz M (2012) Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel) 4:193\u2013217","journal-title":"Cancers (Basel)"},{"key":"2493_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422","journal-title":"N Engl J Med"},{"key":"2493_CR5","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1002\/cncr.24429","volume":"115","author":"CS Higano","year":"2009","unstructured":"Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670\u20133679","journal-title":"Cancer"},{"key":"2493_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez MP, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengelov L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W (2017) Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35:40\u201347","journal-title":"J Clin Oncol"},{"key":"2493_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","volume":"13","author":"AJ van den Eertwegh","year":"2012","unstructured":"van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR (2012) Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:509\u2013517","journal-title":"Lancet Oncol"},{"key":"2493_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.euf.2018.08.016","volume":"4","author":"JK Parsons","year":"2018","unstructured":"Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Kim HL, Nguyen MN, Gulley JL, Jamieson C, Hsu P, Wojtowicz M, Parnes H, Schlom J, Dahut WL, Madan RA, Donahue RN, Chow HS (2018) A randomized, double-blind, phase II trial of PSA-TRICOM (PROSTVAC) in patients with localized prostate cancer: the immunotherapy to prevent progression on active surveillance study. Eur Urol Focus 4:636\u2013638","journal-title":"Eur Urol Focus"},{"key":"2493_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.2016.69.7748","volume":"35","author":"PW Kantoff","year":"2017","unstructured":"Kantoff PW, Gulley JL, Pico-Navarro C (2017) Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer. J Clin Oncol 35:124\u2013125","journal-title":"J Clin Oncol"},{"key":"2493_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099\u20131105","journal-title":"J Clin Oncol"},{"key":"2493_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.23669","volume":"113","author":"CS Higano","year":"2008","unstructured":"Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ (2008) Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:975\u2013984","journal-title":"Cancer"},{"key":"2493_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1586\/erv.12.54","volume":"11","author":"DM Lubaroff","year":"2012","unstructured":"Lubaroff DM (2012) Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 11:857\u2013868","journal-title":"Expert Rev Vaccines"},{"key":"2493_CR13","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","volume":"27","author":"DG McNeel","year":"2009","unstructured":"McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G (2009) Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27:4047\u20134054","journal-title":"J Clin Oncol"},{"key":"2493_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/sj.bjc.6602019","volume":"91","author":"M Pavlenko","year":"2004","unstructured":"Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91:688\u2013694","journal-title":"Br J Cancer"},{"key":"2493_CR15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00262-010-0895-0","volume":"59","author":"S Pejawar-Gaddy","year":"2010","unstructured":"Pejawar-Gaddy S, Rajawat Y, Hilioti Z, Xue J, Gaddy DF, Finn OJ, Viscidi RP, Bossis I (2010) Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother 59:1685\u20131696","journal-title":"Cancer Immunol Immunother"},{"key":"2493_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1158\/0008-5472.CAN-07-0445","volume":"68","author":"ML Garcia-Hernandez","year":"2008","unstructured":"Garcia-Hernandez ML, Gray A, Hubby B, Klinger OJ, Kast WM (2008) Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68:861\u2013869","journal-title":"Cancer Res"},{"key":"2493_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/mt.2011.241","volume":"20","author":"E Spies","year":"2012","unstructured":"Spies E, Reichardt W, Alvarez G, Groettrup M, Ohlschlager P (2012) An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Mol Ther 20:555\u2013564","journal-title":"Mol Ther"},{"key":"2493_CR18","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1073\/pnas.0712269105","volume":"105","author":"M Fasso","year":"2008","unstructured":"Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP (2008) SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)\/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci USA 105:3509\u20133514","journal-title":"Proc Natl Acad Sci USA"},{"key":"2493_CR19","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.4049\/jimmunol.0803663","volume":"183","author":"A Hearn","year":"2009","unstructured":"Hearn A, York IA, Rock KL (2009) The specificity of trimming of MHC class I-presented peptides in the endoplasmic reticulum. J Immunol 183:5526\u20135536","journal-title":"J Immunol"},{"key":"2493_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2174\/156652311798192815","volume":"11","author":"C Coban","year":"2011","unstructured":"Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, Ishii KJ (2011) Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 11:479\u2013484","journal-title":"Curr Gene Ther"},{"key":"2493_CR21","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1016\/j.vaccine.2013.06.063","volume":"31","author":"F Eriksson","year":"2013","unstructured":"Eriksson F, Totterman T, Maltais AK, Pisa P, Yachnin J (2013) DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine 31:3843\u20133848","journal-title":"Vaccine"},{"key":"2493_CR22","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/vaccines2030624","volume":"2","author":"T Ura","year":"2014","unstructured":"Ura T, Okuda K, Shimada M (2014) Developments in viral vector-based vaccines. Vaccines (Basel) 2:624\u2013641","journal-title":"Vaccines (Basel)"},{"key":"2493_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","volume":"21","author":"S Lu","year":"2009","unstructured":"Lu S (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21:346\u2013351","journal-title":"Curr Opin Immunol"},{"key":"2493_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.coph.2019.01.007","volume":"47","author":"TM Calvo","year":"2019","unstructured":"Calvo TM, Allard M, Dutoit V, Dietrich PY, Walker PR (2019) Peptides as cancer vaccines. Curr Opin Pharmacol 47:20\u201326","journal-title":"Curr Opin Pharmacol"},{"key":"2493_CR25","doi-asserted-by":"publisher","first-page":"e1511506","DOI":"10.1080\/2162402X.2018.1511506","volume":"7","author":"L Bezu","year":"2018","unstructured":"Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L (2018) Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology 7:e1511506","journal-title":"Oncoimmunology"},{"key":"2493_CR26","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/cas.13278","volume":"108","author":"W Obara","year":"2017","unstructured":"Obara W, Sato F, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Mimata H, Sugai T, Nakamura Y, Fujioka T (2017) Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci 108:1452\u20131457","journal-title":"Cancer Sci"},{"key":"2493_CR27","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s12272-017-0969-z","volume":"40","author":"R Bastola","year":"2017","unstructured":"Bastola R, Noh G, Keum T, Bashyal S, Seo JE, Choi J, Oh Y, Cho Y, Lee S (2017) Vaccine adjuvants: smart components to boost the immune system. Arch Pharm Res 40:1238\u20131248","journal-title":"Arch Pharm Res"},{"key":"2493_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2217\/nnm-2018-0147","volume":"14","author":"R Wen","year":"2019","unstructured":"Wen R, Umeano AC, Kou Y, Xu J, Farooqi AA (2019) Nanoparticle systems for cancer vaccine. Nanomedicine (Lond) 14:627\u2013648","journal-title":"Nanomedicine (Lond)"},{"key":"2493_CR29","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.4049\/jimmunol.166.9.5346","volume":"166","author":"P Lenz","year":"2001","unstructured":"Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT (2001) Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166:5346\u20135355","journal-title":"J Immunol"},{"key":"2493_CR30","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/eji.200425547","volume":"35","author":"P Lenz","year":"2005","unstructured":"Lenz P, Lowy DR, Schiller JT (2005) Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol 35:1548\u20131556","journal-title":"Eur J Immunol"},{"key":"2493_CR31","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.4049\/jimmunol.173.4.2624","volume":"173","author":"R Yang","year":"2004","unstructured":"Yang R, Murillo FM, Lin KY, Yutzy WH, Uematsu S, Takeda K, Akira S, Viscidi RP, Roden RB (2004) Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol 173:2624\u20132631","journal-title":"J Immunol"},{"key":"2493_CR32","doi-asserted-by":"publisher","first-page":"11152","DOI":"10.1128\/JVI.78.20.11152-11160.2004","volume":"78","author":"R Yang","year":"2004","unstructured":"Yang R, Murillo FM, Cui H, Blosser R, Uematsu S, Takeda K, Akira S, Viscidi RP, Roden RB (2004) Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 78:11152\u201311160","journal-title":"J Virol"},{"key":"2493_CR33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/eji.201343863","volume":"44","author":"JM Saif","year":"2014","unstructured":"Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE (2014) Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. Eur J Immunol 44:994\u20131004","journal-title":"Eur J Immunol"},{"key":"2493_CR34","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00262-016-1831-8","volume":"65","author":"F Cappuccini","year":"2016","unstructured":"Cappuccini F, Stribbling S, Pollock E, Hill AV, Redchenko I (2016) Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother 65:701\u2013713","journal-title":"Cancer Immunol Immunother"},{"key":"2493_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jconrel.2012.06.015","volume":"162","author":"M Mueller","year":"2012","unstructured":"Mueller M, Reichardt W, Koerner J, Groettrup M (2012) Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J Control Release 162:159\u2013166","journal-title":"J Control Release"},{"key":"2493_CR36","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","volume":"92","author":"NM Greenberg","year":"1995","unstructured":"Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439\u20133443","journal-title":"Proc Natl Acad Sci USA"},{"key":"2493_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/sj.pcan.4500296","volume":"2","author":"JR Gingrich","year":"1999","unstructured":"Gingrich JR, Barrios RJ, Foster BA, Greenberg NM (1999) Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2:70\u201375","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2493_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lfs.2018.12.002","volume":"217","author":"LA Kido","year":"2019","unstructured":"Kido LA, de Almeida LC, Marostica MR Jr, Cagnon VHA (2019) Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: a good alternative to study PCa progression and chemoprevention approaches. Life Sci 217:141\u2013147","journal-title":"Life Sci"},{"issue":"Suppl 6","key":"2493_CR39","doi-asserted-by":"publisher","first-page":"G52","DOI":"10.1016\/j.vaccine.2009.09.106","volume":"27","author":"A Gray","year":"2009","unstructured":"Gray A, de la Garcia-Hernandez L, van WM, Kanodia S, Hubby B, Kast WM, (2009) Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 27(Suppl 6):G52\u2013G59","journal-title":"Vaccine"},{"key":"2493_CR40","first-page":"2444","volume":"60","author":"AA Hurwitz","year":"2000","unstructured":"Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444\u20132448","journal-title":"Cancer Res"},{"key":"2493_CR41","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.vaccine.2010.12.016","volume":"29","author":"M Krupa","year":"2011","unstructured":"Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M (2011) Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 29:1504\u20131513","journal-title":"Vaccine"},{"key":"2493_CR42","doi-asserted-by":"publisher","first-page":"28194","DOI":"10.18632\/oncotarget.4442","volume":"6","author":"AR Kwilas","year":"2015","unstructured":"Kwilas AR, Ardiani A, Dirmeier U, Wottawah C, Schlom J, Hodge JW (2015) A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model. Oncotarget 6:28194\u201328210","journal-title":"Oncotarget"},{"key":"2493_CR43","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1158\/0008-5472.CAN-13-2685","volume":"74","author":"J Fu","year":"2014","unstructured":"Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ (2014) Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 74:4042\u20134052","journal-title":"Cancer Res"},{"key":"2493_CR44","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-03-0946","volume":"64","author":"SB Shappell","year":"2004","unstructured":"Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270\u20132305","journal-title":"Cancer Res"},{"key":"2493_CR45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s13365-015-0420-5","volume":"22","author":"SE Beck","year":"2016","unstructured":"Beck SE, Queen SE, Viscidi R, Johnson D, Kent SJ, Adams RJ, Tarwater PM, Mankowski JL (2016) Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control. J Neurovirol 22:498\u2013507","journal-title":"J Neurovirol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02493-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:50:20Z","timestamp":1612313420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02493-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2493"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02493-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Raphael P Viscidi is the inventor of the bovine VLP vaccine technology and could financially benefit if a product based on the technology is commercialized. All other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal procedures were performed according to NIH guidelines under protocol MO17M189 approved by the Johns Hopkins University Animal Care and Use Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Breeding pairs of TRAMP mice (C57BL\/6-Tg(TRAMP)8247Ng\/J)(stock no. 003135) and wild type C57BL\/6\u00a0J mice (stock no. 000664) were purchased from Jackson Laboratories (Bar Harbor, ME). Tramp mice were bred within our colony on a pure C57BL\/6 background.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal rights"}},{"value":"High Five\u2122 Cells (BTI-TN-5B1-4) are a clonal isolate derived from the parental <i>Trichoplusia ni<\/i> cell line (cabbage looper ovary) and are adapted to serum-free culture (Thermo Fisher Scientific, #B85502). The cells were not further authenticated as they are of insect origin and were used for protein production only.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}